Kenalog-10 (triamcinolone acetonide) / BMS - LARVOL DELTA

Elucidating medication waste for outpatient clinic procedures with intralesional triamcinolone (SID 2025) - "We conducted a retrospective chart review for patients receiving intralesional steroid injections with Kenalog-40 or Kenalog-10 at our academic institution from 01/01/2020–12/31/2023 for the treatment of scars, keloids, or different types of alopecia. Our results highlight an urgent opportunity to reduce unnecessary medical waste from single-use medications and the importance of considering how our daily practice affects our environmental impact. Encouraging sustainable practices such as optimizing medication dosing and preparation, implementing a return program for unused medication, and increasing awareness may help minimize medical waste in dermatology."

Clinical • Alopecia • Dermatology • Fibrosis • Immunology

Jak Inhibitor in a Refractory Case of penile HS (EADV 2024) - "First line of treatment included PO clindamycin, topical clindamycin, and benzoyl peroxide 10% solution...Therapy was escalated to 1cc of intralesional kenalog-10 injected into each lesion, moxifloxacin 400 mg daily, metronidazole 500 mg TID, and rifampin 300 mg BID along with topicals due to increased serosanguinous discharge from the area along with fever, tachycardia, and leukocytosis. As he was still not improving, the patient was then started on the biologic adalimumab, a TNF blocker...The patient failed several additional treatments including PO steroids, IV ertapenem, and seculuzimab (IL-17A inhibitor) . He was also poorly controlled on infliximab (TNF alpha inhibitor) even when maxing out the infliximab dose to 10 mg/kg q4 weeks. Due to complications and poor control of HS in this patient, he will now be started on Tofacitinib (Jak inhibitor) in addition to a TNF alpha inhibitor for greater benefit. Additionally, cyclosporine was used as an off-label treatment to..."

Clinical • Cardiovascular • Dermatology • Hidradenitis Suppurativa • Pain • IL17A

Cheilitis Granulomatosa: A Case Review (AAOMS 2024) - "Multiple case reports discussing treatment of CG include the use of systemic corticosteroids, topical clobetasol or triamcinolone, as well as the use of dapsone.1 Treatment with 4 courses of local intralesional corticosteroid therapy (Kenalog 10mg/mL) resulted in remission after 3 months. Medications including glucocorticoids (systemic, topical, intralesional), immunomodulators (clofazimine, hydroxychloroquine, fumaric acid esters), antibiotics (macrolides, tetracyclines, metronidazole), monoclonal antibodies, immunosuppressants (methotrexate, azathioprine), biologics (anti-tumor necrosis factor alpha [TNF-α]), and laser therapy have been documented in the treatment of GC6. The authors found success with a series of 4 intralesional corticosteroid injections (Kenalog 10mg/mL, 20 units per visit) resulted in remission after 3 months."

Clinical • Review • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hemophilia • Immunology • Inflammatory Bowel Disease • Oncology • TNFA

Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: NYU Langone Health | Terminated ➔ Withdrawn

Trial withdrawal • Immunology • Rheumatology

Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis (clinicaltrials.gov) - P2 | N=1 | Terminated | Sponsor: NYU Langone Health | N=32 ➔ 1 | Trial completion date: Jan 2024 ➔ May 2023 | Recruiting ➔ Terminated | Trial primary completion date: Sep 2023 ➔ May 2023; Difficulties getting subjects recruited and enrolled.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Immunology • Rheumatology

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis (clinicaltrials.gov) - P4 | N=10 | Completed | Sponsor: Weill Medical College of Cornell University | Recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Mar 2023

Trial completion • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis (clinicaltrials.gov) - P4 | N=10 | Recruiting | Sponsor: Weill Medical College of Cornell University | Trial primary completion date: Jun 2022 ➔ Dec 2022

Trial primary completion date • Dermatology • Immunology • Psoriasis

Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: NYU Langone Health | Not yet recruiting ➔ Recruiting | Trial completion date: Jan 2023 ➔ Jan 2024 | Initiation date: Sep 2021 ➔ May 2022 | Trial primary completion date: Sep 2022 ➔ Sep 2023

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Rheumatology

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis (clinicaltrials.gov) - P4; N=10; Recruiting; Sponsor: Weill Medical College of Cornell University; Trial completion date: Dec 2020 ➔ Dec 2022; Trial primary completion date: Dec 2020 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Dermatology • Immunology • Psoriasis

Autologous Intra-Articular Micro-Fragmented Adipose Transfer for the Treatment of Thumb Carpometacarpal Joint Arthritis (clinicaltrials.gov) - P2; N=32; Not yet recruiting; Sponsor: NYU Langone Health

New P2 trial • Immunology • Rheumatology

Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata (clinicaltrials.gov) - P2; N=14; Completed; Sponsor: University of Minnesota; Phase classification: P=N/A ➔ P2

Clinical • Phase classification • Alopecia

Injection of Hyaluronic Acid Versus Corticosteroid for Treatment of Trigger Finger (clinicaltrials.gov) - P1; N=100; Recruiting; Sponsor: Dubai Health Authority

Clinical • New P1 trial

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis (clinicaltrials.gov) - P4; N=10; Recruiting; Sponsor: Weill Medical College of Cornell University; Initiation date: Dec 2019 ➔ Mar 2020

Clinical • Trial initiation date

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis (clinicaltrials.gov) - P4; N=10; Recruiting; Sponsor: Weill Medical College of Cornell University

Clinical • New P4 trial